Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Tumor cell-educated periprostatic adipose tissue acquires an aggressive cancer-promoting secretory profile.

Ribeiro RJ, Monteiro CP, Cunha VF, Azevedo AS, Oliveira MJ, Monteiro R, Fraga AM, Príncipe P, Lobato C, Lobo F, Morais A, Silva V, Sanches-Magalhães J, Oliveira J, Guimarães JT, Lopes CM, Medeiros RM.

Cell Physiol Biochem. 2012;29(1-2):233-40. doi: 10.1159/000337604. Epub 2012 Mar 1.

2.

Human periprostatic adipose tissue: its influence on prostate cancer cells.

Sacca PA, Creydt VP, Choi H, Mazza ON, Fletcher SJ, Vallone VB, Scorticati C, Chasseing NA, Calvo JC.

Cell Physiol Biochem. 2012;30(1):113-22. doi: 10.1159/000339051. Epub 2012 Jun 13.

3.

Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro.

Ribeiro R, Monteiro C, Cunha V, Oliveira MJ, Freitas M, Fraga A, Príncipe P, Lobato C, Lobo F, Morais A, Silva V, Sanches-Magalhães J, Oliveira J, Pina F, Mota-Pinto A, Lopes C, Medeiros R.

J Exp Clin Cancer Res. 2012 Apr 2;31:32. doi: 10.1186/1756-9966-31-32.

4.

Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness.

Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, Zaldivar F, Santos R, Tyson DR, Ornstein DK.

J Urol. 2009 Oct;182(4):1621-7. doi: 10.1016/j.juro.2009.06.015. Epub 2009 Aug 15.

PMID:
19683746
5.
6.

Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.

Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, Yki-Jărvinen H, Back DJ, Pirmohamed M, Gazzard BG, Walker UA, Moyle GJ.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):565-72.

PMID:
16284533
7.
8.

MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation.

Allott EH, Lysaght J, Cathcart MC, Donohoe CL, Cummins R, McGarrigle SA, Kay E, Reynolds JV, Pidgeon GP.

Mol Carcinog. 2013 Feb;52(2):144-54. doi: 10.1002/mc.21840. Epub 2011 Nov 28.

PMID:
22121096
9.

Periprostatic adipose tissue and prostate cancer progression: new insights into the tumor microenvironment.

Toren P, Venkateswaran V.

Clin Genitourin Cancer. 2014 Feb;12(1):21-6. doi: 10.1016/j.clgc.2013.07.013. Epub 2013 Oct 24. Review. No abstract available.

PMID:
24269373
10.

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.

Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC, Eaton CL.

J Bone Miner Res. 2004 Oct;19(10):1712-21. Epub 2004 Jul 7.

11.

Regulation of adiponectin release and demonstration of adiponectin mRNA as well as release by the non-fat cells of human omental adipose tissue.

Fain JN, Buehrer B, Tichansky DS, Madan AK.

Int J Obes (Lond). 2008 Mar;32(3):429-35. Epub 2007 Sep 25.

PMID:
17895880
12.

Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells.

Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, Cha TL, Sun GH.

Cancer Sci. 2008 May;99(5):905-13. doi: 10.1111/j.1349-7006.2008.00756.x. Epub 2008 Feb 18.

13.

A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis.

Patel ST, Mistry T, Brown JE, Digby JE, Adya R, Desai KM, Randeva HS.

Peptides. 2010 Jan;31(1):51-7. doi: 10.1016/j.peptides.2009.10.001. Epub 2009 Oct 9.

PMID:
19819277
14.

Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression.

Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, Travali S, Stivala F, Canevari S, Libra M.

Clin Cancer Res. 2008 Nov 15;14(22):7470-80. doi: 10.1158/1078-0432.CCR-08-0870.

15.

Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells.

Millimaggi D, Festuccia C, Angelucci A, D'Ascenzo S, Rucci N, Flati S, Bologna M, Teti A, Pavan A, Dolo V.

Int J Oncol. 2006 Apr;28(4):909-14.

PMID:
16525640
16.

Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.

Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM.

Cancer Res. 2001 Jul 15;61(14):5652-9.

17.

Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells.

Uemura H, Ishiguro H, Nagashima Y, Sasaki T, Nakaigawa N, Hasumi H, Kato S, Kubota Y.

Mol Cancer Ther. 2005 Nov;4(11):1699-709.

18.

CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells.

Hu W, Zhen X, Xiong B, Wang B, Zhang W, Zhou W.

Cancer Sci. 2008 Jul;99(7):1362-9. doi: 10.1111/j.1349-7006.2008.00833.x. Epub 2008 Apr 29. Erratum in: Cancer Sci. 2008 Dec;99(12):2548.

19.

CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.

Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G, Ye YK, Liang YX, Qin WJ, Zhang Z, Zeng GH, Chen ZN.

Oncology. 2008;75(3-4):230-6. doi: 10.1159/000163852. Epub 2008 Oct 14.

PMID:
18852494
20.

Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts.

Kaminski A, Hahne JC, Haddouti el-M, Florin A, Wellmann A, Wernert N.

Int J Mol Med. 2006 Nov;18(5):941-50.

PMID:
17016625

Supplemental Content

Support Center